Indianapolis, IN – February 2026 – Eli Lilly and Company reported exceptional full-year financial and operational performance in 2025, driven by unprecedented demand for its metabolic disease portfolio, strong execution across oncology, and sustained investment in long-term innovation. The results highlight Lilly’s evolution into a scaled, science-led biopharmaceutical leader with global impact across chronic and complex diseases.
“In 2025, Lilly delivered breakthrough performance that reached more patients than ever before,” said David A. Ricks, Chairman and Chief Executive Officer, Eli Lilly and Company.
“Our metabolic disease therapies have become foundational to global care paradigms, and our diversified pipeline positions us for continued innovation and long-term leadership.”
2025 Financial and Operational Highlights
- Total Revenue: $65.2 billion in 2025
- Net Income: $20.6 billion
- Research & Development Investment: $13.3 billion, representing approximately 20.5% of total revenue
Lilly’s 2025 performance reflects strong commercial execution across core therapeutic areas, supported by continued expansion of manufacturing capacity and sustained reinvestment in scientific innovation.
Metabolic Disease & Incretin Therapies: Core Growth Engine
Lilly’s metabolic disease portfolio was the dominant contributor to revenue and growth in 2025, reshaping treatment standards in diabetes, obesity, and cardiometabolic disease.
MOUNJARO® (tirzepatide)
- 2025 Global Sales: $22.97 billion
MOUNJARO continued to demonstrate strong global adoption in type 2 diabetes, driven by robust clinical outcomes, expanding reimbursement coverage, and increased physician utilization across major markets.
“MOUNJARO has become a cornerstone of modern metabolic care,” said Dr. Daniel M. Skovronsky, Chief Scientific Officer and President, Lilly Research Laboratories.
“Its impact reflects the strength of our discovery platform and our commitment to advancing therapies that deliver meaningful, durable benefits for patients.”
ZEPBOUND® (tirzepatide for obesity)
- 2025 Global Sales: $13.54 billion
ZEPBOUND established rapid momentum in obesity management during 2025, reflecting substantial unmet medical need and strong clinical differentiation. Adoption accelerated across markets as access expanded and physician awareness increased.
Together, MOUNJARO and ZEPBOUND generated more than $36.5 billion in combined sales in 2025, firmly establishing Lilly as the global leader in incretin-based metabolic therapies.
Oncology: Expanding a Durable Growth Pillar
Lilly’s oncology franchise continued to provide portfolio diversification and long-term growth potential.
VERZENIO® (abemaciclib)
- 2025 Global Sales: $5.72 billion
VERZENIO maintained strong demand across early-stage and metastatic hormone receptor-positive breast cancer, reinforcing Lilly’s position in precision oncology.
“Our oncology strategy is grounded in differentiated science and clear clinical value,” Dr. Skovronsky added.
“VERZENIO’s continued performance reflects our focus on therapies that meaningfully improve outcomes across the cancer continuum.”
Lilly also advanced multiple oncology pipeline assets in 2025, including next-generation targeted therapies and antibody-drug conjugates.
Portfolio Breadth and Emerging Areas
Beyond metabolic disease and oncology, Lilly continued to invest in:
- Immunology, with ongoing lifecycle management of marketed assets and advancement of novel mechanisms
- Neuroscience, including late-stage programs addressing neurodegenerative and neuropsychiatric disorders
- Cardiometabolic outcomes research, supporting broader disease modification strategies
Research, Development, and Manufacturing Scale
Lilly’s $13.3 billion R&D investment in 2025 supported one of the industry’s deepest late-stage pipelines. The company also accelerated global manufacturing expansion, particularly for injectable and oral metabolic therapies, to support sustained demand and long-term access.
Strategic focus areas included:
- Next-generation incretin and oral metabolic therapies
- Precision oncology platforms
- Neuroscience disease-modifying approaches
- Global supply chain resilience and capacity expansion
“We are building Lilly not just for today’s demand, but for the next decade of innovation,” Ricks said.
“Our investments in science and manufacturing are designed to ensure sustainable access while advancing transformational medicines.”
Strategic Outlook
Looking ahead, Lilly’s long-term strategy is centered on:
- Scaling leadership in diabetes and obesity, driven by continued expansion of tirzepatide-based therapies
- Extending cardiometabolic impact, through outcomes-focused clinical programs
- Building oncology as a durable growth pillar, supported by precision and targeted platforms
- Advancing high-risk, high-reward science, particularly in neuroscience
- Sustaining global manufacturing expansion, to support long-term patient access
“Lilly enters the next phase of growth with unmatched momentum, scientific depth, and executional strength,” Ricks concluded.
“Our focus remains clear: deliver life-changing medicines today while building a company positioned for long-term global impact.”
About Eli Lilly and Company
Eli Lilly and Company is a global pharmaceutical leader dedicated to discovering and delivering innovative medicines that improve health outcomes worldwide. With leadership in metabolic disease, oncology, immunology, and neuroscience, Lilly is committed to advancing science to address some of the world’s most pressing health challenges.
By
